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ABSTRACT
Introduction Obese men with prostate cancer have an
increased risk of biochemical recurrence, metastatic
disease and mortality. For those undergoing androgen
deprivation therapy (ADT), substantial increases in
fat mass are observed in the first year of treatment.
Recently, we showed that a targeted supervised clinic-
based exercise and nutrition intervention can result
in a substantial reduction in fat mass with muscle
mass preserved in ADT-treated patients. However, the
intervention needs to be accessible to all patients and
not just those who can access a supervised clinic-based
programme. The purpose of this study was to evaluate the
efficacy of telehealth delivered compared with supervised
clinic-based delivered exercise and nutrition intervention in
overweight/obese patients with prostate cancer.
Methods and analysis A single-blinded, two-arm parallel
group, non-inferiority randomised trial will be undertaken
with 104 overweight/obese men with prostate cancer
(body fat percentage ≥25%) randomly allocated in a
ratio of 1:1 to a telehealth-delivered, virtually supervised
exercise and nutrition programme or a clinic-based, face-
to-face supervised exercise and nutrition programme.
Exercise will consist of supervised resistance and aerobic
exercise performed three times a week plus additional
self-directed aerobic exercise performed 4 days/week
for the first 6 months. Thereafter, for months 7–12, the
programmes will be self-managed. The primary endpoint
will be fat mass. Secondary endpoints include lean
mass and abdominal aortic calcification, anthropometric
measures and blood pressure assessment, objective
measures of physical function and physical activity
levels, patient-reported outcomes and blood markers.
Measurements will be undertaken at baseline, 6 months
(post intervention), and at 12 months of follow-up. Data
will be analysed using intention-to-treat and per protocol
approaches.
Ethics and dissemination Ethics approval has been
obtained from the Edith Cowan University Human Research

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ Direct comparison between telehealth and clinic-

based supervised exercise and nutrition programme
in obese/overweight men with prostate cancer.
⇒ Year-long trial comprising 6 months of direct intervention followed by 6 months of self-management.
⇒ Comprehensive assessment of objective and
patient-reported outcomes including dual-energy X-
ray absorptiometry for the primary outcome.
⇒ The study is limited to patients previously treated or
currently undergoing androgen deprivation therapy.

Ethics Committee (ID: 2021–02157-GALVAO). Outcomes
from the study will be published in academic journals and
presented in scientific and consumer meetings.
Trial registration number ACTRN12621001312831.

INTRODUCTION
Prostate cancer is one of the most prevalent cancers worldwide, accounting for ~1.4
million new cancer cases and more than
300 000 deaths in 2020.1 Among the treatments available, androgen deprivation
therapy (ADT) has been extensively used in
the management of localised and advanced
disease to delay cancer progression and
improve survival.2 However, several adverse
effects including increases in fat mass and
reductions in muscle mass are common
especially during the first year of ADT,3
increasing or aggravating obesity and metabolic syndrome.4 In turn, obesity increases
the risk of complications during radical prostatectomy and radiation therapy,5 6 as well as
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Figure 1 Consolidated Standards of Reporting Trials
diagram depicting the participants throughout the trial. ADT,
androgen deprivation therapy.

METHODS AND ANALYSIS
This is a single-
blinded, two-
arm parallel group, non-
inferiority randomised trial designed to examine the
efficacy of implementing a telehealth-delivered, virtual
supervised, exercise and nutrition (TENUT) programme
compared with a clinic-
based, face-
to-
face supervised
exercise and nutrition (CENUT) programme on fat
mass in overweight/obese men with prostate cancer
(figure 1). The protocol has been approved (ID: 2021–
02157-GALVAO) by the Edith Cowan University Human
Research Ethics Committee. This trial expects to enrol
participants to baseline testing between December 2021
and December 2023.

Patients and methods
One-hundred and four overweight/obese men (52 participants per arm) undergoing treatment or previously
treated (ie, those who had completed treatment and are
no longer on treatment) for prostate cancer involving
ADT will be identified and recruited through attending
physicians (general practitioner/radiation oncologist/
urologist), specialist nurses, advertisements in local newspapers and presentations at cancer support groups and
related events in Western Australia. Inclusion criteria
are (1) body fat percentage of ≥25%26 and (2) ability to
walk 400 m. Exclusion criteria are (1) acute illness or any
musculoskeletal, cardiovascular or neurological disorder
that could inhibit exercise performance or put participants at risk from exercising, and (2) inability to read and
understand English. Eligible patients will undertake baseline measurements prior to randomisation. All patients
must provide written informed consent prior to participation in addition to a physician clearance form. The
study coordinator will obtain the consent and clearance
forms from patients and physicians. Patients with metastases will be required to present their last bone imaging
scan to establish location and extent of bone lesions with
the exercise prescription modified according to Galvão et
al12 and to the Exercise and Sports Science Australia exercise and cancer position statement.27 All data relevant to
the study will be kept on password-encrypted computers
accessible only by study investigators situated in the
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the risk of biochemical recurrence, metastatic disease
and mortality.7–9
We10–17 and others18–23 have shown that exercise can
counteract several treatment-
related toxicities such as
reducing or mitigating fatigue, improving muscle mass
and strength, bone mass and physical function during or
following ADT. However, the effects of exercise alone on
fat mass are modest with reductions of ~0.7 kg observed
in a recent meta-analysis of overweight men with prostate
cancer17 compared with the substantial gains of ~2.3 kg
that can be experienced during the first year of treatment.3 As a result, exercise undertaken in trials to date
has been largely insufficient to counteract the treatment-
related gains in fat mass, which may be especially problematic for men already overweight or obese.
Recently, we presented new evidence that in obese
ADT-
treated patients with prostate cancer, a targeted
and supervised clinic-based 12-week exercise programme
allied with protein supplementation and energy restriction resulted in a substantial reduction of ~2.8 kg in fat
mass while preserving muscle mass.24 However, it is necessary to expand such programmes to alternative exercise settings where overweight/obese patients living in
underserved areas, such as those in regional and rural
settings, or those without the financial capacity to access
such programmes. Recently, telehealth has emerged as a
viable method to deliver health-related services such as
exercise and nutrition interventions25 and, if effective in
this group of patients with prostate cancer, could be available at a lower cost and reach larger numbers of patients
irrespective of their geographical location. Therefore,
we propose to undertake a 6-
month non-
inferiority
randomised trial to evaluate the efficacy of a telehealth
delivered compared with a supervised clinic-based delivered exercise and nutrition intervention in overweight
and obese patients with prostate cancer. We will compare
our previously reported supervised clinic-based exercise
and nutrition weight loss programme24 to a programme
modified for delivery via telehealth in overweight/obese
men with prostate cancer, with subsequent follow-up over
6 months to monitor sustainability. The primary outcome
will be fat mass with secondary outcomes including lean
mass and objective and patient-reported outcomes.

Open access

Patient and public involvement
We conducted a health consumer workshop reaching out
to 14 men with prostate cancer who had completed our
most recent exercise and nutrition intervention study.24
The men were overweight or obese and completed the
3-month diet and exercise programme in our exercise
clinics. We sought their input on the programme they
had just completed and how they would view a telehealth
intervention. This input was used to inform this project
and ensure that it engages participants in a respectful,
ethical and impactful way. We also worked closely with the
Prostate Cancer Foundation of Australia (PCFA), their
support groups and state offices. As the project evolves,
PCFA will assist in the dissemination of findings to cancer
support groups and the general public, while study participants will receive their individual results as well as overall
study findings.
Randomisation
Patients will be randomly allocated by a computer
random assignment programme to the two study arms:
(1) TENUT and (2) CENUT in a ratio of 1:1, subject to
maintaining approximate balance regarding stratification
for time on ADT (<6 months, ≥6 months and previous
ADT). An investigator with no patient contact will be
responsible for randomisation. The allocation sequence
will be concealed from exercise physiologists involved in

assigning participants to groups or conducting the study
measures. In addition, participants will be requested to
not reveal their group allocation to any members of the
research team. The exercise will be provided by exercise
physiologists not in the research team or performing the
tests.
Measurements
All measurement study endpoints will take place at baseline, 6 months (end of intervention) and 12 months (6
months post intervention) and will be undertaken in
person at the Exercise Medicine Research Institute at
Edith Cowan University in Perth, Australia (figure 2).
All assessment tools/procedures have established validity
and reliability and are used widely in clinical research
including by our team.10–15
Study endpoints
Primary study endpoint
Fat mass
Regional and whole-body fat mass will be derived from
a whole-
body dual-
energy X-
ray absorptiometry (DXA,
Horizon A; Hologic, Waltham, Massachusetts, USA) scan.
Trunk adiposity, visceral fat and adipose indices will be
assessed using standard procedures.13 14 28
Secondary study endpoints
Lean mass and abdominal aortic calcification
Regional and whole-body lean mass will be assessed by
DXA. In addition, lateral spine images will be collected

Figure 2 Study design, exercise and nutrition interventions and timeline assessments. BSI-18, Brief Symptom Inventory-18;
3d-WR, 3-day weighed food record; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality
of Life Questionnaire 30; EORTC QLQ-PR25,European Organization for Research and Treatment of Cancer Prostate Cancer-
Specific Module; FACIT-Fatigue, Functional assessment of Chronic Illness Therapy–Fatigue; IGF1, insulin-like-growth factor-1;
IGFBP3, IGF-binding protein-3; IL, interleukin; PSA, prostate-specific antigen; TNF-α, tumour necrosis factor alpha.
Galvão DA, et al. BMJ Open 2022;12:e058899. doi:10.1136/bmjopen-2021-058899
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Exercise Medicine Research Institute (Perth, Western
Australia, Australia).
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Anthropometric measures and blood pressure assessment
Central adiposity will be assessed by waist circumference (WC) and hip circumference (HC).30 WC will be
measured at the level of the narrowest point between the
lower costal (rib) border and the iliac crest. HC will be
measured at the level of the greatest posterior protuberance of the buttocks, which usually corresponds anteriorly to the level of the symphysis pubis. Body mass index
(kg/m2) will also be used to assess weight (kg) relative
to height (m) squared. A validated oscillometric device
(HEM-705CP, Omron Corporation, Japan) will be used
to record brachial systolic and diastolic blood pressures at
the dominant arm in triplicate.
Objective measures of physical function and physical activity
levels
A battery of standard tests will be used to assess physical
function: (1) one-
repetition maximum (1RM) test for
chest press and leg press strength, (2) submaximal cycle
ergometer test for estimation of maximal oxygen uptake
(VO2max), (3) 400 m walk test for aerobic capacity and
walking endurance, (4) repeated chair rise for lower body
function, (5) 6 m usual and fast walk for gait speed and (6)
6 m backwards tandem walk for dynamic balance.11–15 31
Self-reported physical activity will be assessed by the leisure
score index from the Godin Leisure-Time Exercise Questionnaire modified to include a question on resistance
training.32
Intervention adherence and monitoring
Adherence to the direct supervised exercise component will be defined as the number of sessions attended
divided by the total number of sessions scheduled in both
TENUT (ie, telehealth programme) and CENUT (clinic-
based programme) groups. For the self-managed phase
of the study, patients in the TENUT will continue with the
digital platform for recording, while the CENUT group
will receive a self-managed exercise log with instructions
to be completed.
Adherence to dietary recommendations will be assessed
using an adapted customised adherence questionnaire24 33 34 designed to provide an estimated frequency
of consumption and number of serves of food of interest
based on the nutrition advice given. Food items of interest
include fruit and vegetables, nuts, high protein foods,
dairy, grains and cereals, beverages and alcoholic drinks,
discretionary and take-away items. Patients will be asked
25 yes/no questions, where a score of 1 is given if the
patient met a predetermined desired outcome, or a 0 if
they did not. A higher total score indicates greater compliance with a maximum score of 25. For nutrition monitoring, patients will complete a 3-day weighed food record
(3d-WR) over three consecutive days (one weekend day
and two weekdays) at baseline and 6 and 12 months. This
will provide an estimate of total energy intake (kJ/d) and
4

macro- and micronutrients consumed. The 3d-WR data
will be analysed using FoodWorks (FoodWorks 10 Professional, Xyris Software Pty, Queensland, Australia).
Patient-reported outcomes
Health-related quality of life will be assessed using the
Medical Outcomes Short Form 36,35 while cancer-related
quality of life will be measured using the EORTC QLQ-
C30 (European Organization for Research and Treatment of Cancer Prostate Cancer-Specific Module)36 and
the EORTC-PR25 (European Organization for Research
and Treatment of Cancer Quality of Life Questionnaire
30) for disease-
specific health-
related quality of life.37
Fatigue will be assessed using the Functional assessment of
Chronic Illness Therapy–Fatigue questionnaire. The Brief
Symptom Inventory-18 will be used to assess psychological distress across the domains of anxiety, depression and
somatisation, and global distress severity.38 These validated
instruments are an integrated system to assess quality of
life and psychological distress in patients with cancer and
has been extensively employed in clinical trials of exercise
medicine.10–13 39 In addition, the Masculinity in Chronic
Disease Index will be used to assess the extent to which
men identify with six masculine values: strength, sexual
importance/priority, family responsibilities, emotional
self-reliance, optimistic capacity and action approach,40 41
while an adapted Working Alliance Inventory for General
Practice tool will be used to identify and explain the
mechanism or process that underlies the delivery of exercise and nutrition as well as benefits derived from these
programmes in men with prostate cancer.42 43
Blood markers
Testosterone, prostate-
specific antigen (PSA), lipid
profile, insulin, glucose, glycated haemoglobin, C reactive protein, adiponectin, leptin, insulin-
like-
growth
factor-1 (IGF1), IGF-binding protein-3 (IGFBP3), interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-α)
will be measured commercially by an accredited Australian National Association of Testing Authorities laboratory (Pathwest Diagnostics, Perth, Western Australia,
Australia).11 13 24
Safety and monitoring
Patients will be monitored for any adverse events during
training and testing by accredited exercise physiologists (AEPs) with study clinicians overseeing aspects of
patient management where required. During the self-
management phase of the study, participants will record
any adverse events which will be monitored by AEPs via
monthly phone calls. The National Cancer Institute’s
Common Terminology Criteria for Adverse Events V.5.0
will be used for grading the severity of adverse events
during the study.44
Exercise interventions
Telehealth and face-to-face delivered exercise and nutrition
programmes
The interventions will consist of 300 min/week of
moderate to vigorous exercise per week for 6 months
Galvão DA, et al. BMJ Open 2022;12:e058899. doi:10.1136/bmjopen-2021-058899
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Calculation of sample size and statistical analysis
From our previous research in obese patients with
prostate cancer, we reported that the SD for change in
fat mass equates to 2.6 kg (mean change of −2.8 kg)
following 3 months of combined resistance and aerobic
exercise with protein supplementation and caloric restriction.24 A priori, 43 patients per group will be required
Galvão DA, et al. BMJ Open 2022;12:e058899. doi:10.1136/bmjopen-2021-058899

to achieve 80% power at an α level of .025 (one-tailed)
and to demonstrate a non-inferiority limit below 1.4 kg
of fat mass between the TENUT and CENUT groups.
Therefore, to adequately ensure that we have a sufficient number of participants at the end of the study
(accounting for a drop-out rate of 20%), 52 participants
will be randomised to each group.
Normality of the data will be assessed using the
Kolmogorov-
Smirnov test. Baseline characteristics will
be analysed using Student’s t-tests or the Mann-Whitney
U test for continuous measures, as appropriate, and χ2
for categorical variables. For the study outcomes, data
will be analysed using intention-to-treat and per protocol
approaches. Testing for longitudinal changes will be
performed using linear mixed models. Non-inferiority of
the intervention for the primary outcome will be implied
if the lower limit of a one-sided 95% CI of the difference
between groups between baseline and 6 months is within
the prestated limit of 1.4 kg for fat mass change.
ETHICS AND DISSEMINATION
Outcomes from the study will be published in peer-
reviewed academic journals and presented in scientific,
consumer and clinical meetings. The study investigators
and trial coordinator will have access to the data.
DISCUSSION
Men with prostate cancer undergoing ADT experience
increased fat and reduced muscle mass, placing them at
increased risk of morbidity and mortality from cardiovascular and metabolic diseases.3 8 45 46 Targeted exercise
medicine interventions for men with prostate cancer
can improve quality of life, reduce treatment-
related
side effects and improve both physical and psychological
health.10–17 More recently, we have shown that in obese
men with prostate cancer, a targeted supervised clinic-
based exercise and nutrition intervention resulted in a
substantial reduction in fat mass (~3 kg), while muscle
mass was preserved.24 This is a new finding; however, availability of these clinic-based services and patient support
is limited and the vast majority of patients cannot access
due to issues of distance, transport, inconvenience and
financial capacity. The result is an unacceptable disparity
between patients who have access to such supportive care
and those who do not, resulting in suboptimal quality of
life and, ultimately, survival for those men who cannot
access current best practice care.
These issues are particularly pertinent to patients in
Western Australia due to our geography (comprises about
a third of the country with only one major metropolitan
area), resulting in the majority of men with prostate
cancer having limited or no capacity to access exercise
and nutrition programmes face-to-face with health professionals. Access to the latest exercise medicine and nutrition services has been unfortunately further impacted
by the COVID-19 pandemic due to personal isolation,
5
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comprising a supervised resistance and aerobic exercise
programme performed three times per week for 60 min
per session delivered face-to-face in an exercise clinic or
via telehealth by AEP, plus 30 min of moderate/vigorous
physical activity self-
managed 4 days/week. For both
TENUT and CENUT, resistance training will comprise
two to four sets for six to eight exercises targeting the
major upper and lower body muscle groups performed
using equipment such as exercise machines, dumbbells and elastic bands at an intensity of 6–12 repetition
maximum (ie, the maximal weight that can be lifted 6–12
times, which is equivalent to ~60% to 85% of 1RM). The
supervised aerobic exercise component will involve 15 to
20 min of moderate to vigorous intensity cardiovascular
exercise using a variety of modes such as walking, jogging
or cycling. This approach has been extensively used
by our team,11 13 14 24 providing optimal stimulus while
maximising safety, compliance and retention in clinic-
based exercise programmes. The self-
directed aerobic
component will comprise these modes for 30 min 4 days/
week. For the telehealth intervention, we will implement
the latest digital platforms that we developed during
COVID-
19 restrictions in 2020 and related technological advancements in wearable sensors (Fitbit Charge 5,
Fitbit, USA), online monitoring and video chat (Microsoft Teams, Microsoft, Redmond, Washington, USA) and
cloud-
based platforms (MyWellness TechnoGym Cloud
platform, TechnoGym Australia Pty, Australia). Participants will receive their exercise programme via their
smart device or computer, communicate with the AEP
and fellow participants by video chat, and be monitored
in real-time through the internet.
For the nutrition intervention, all participants will
receive a total of five face-
to-
face or online consultations over the first 6 months of intervention (baseline,
2, 12, 18 and 24 weeks) with an accredited practising
dietitian (APD) aiming to (1) achieve an energy deficit
of 2100–4200 kJ/day (500–1000 kcal/day); (2) reducing
discretionary items including alcoholic drinks and foods
containing refined sugars and (3) maintain protein
intake. In addition, participants will consume 40 g of a
whey protein supplement three times per week immediately after the resistance exercise sessions.
At the end of the first 6-month period, participants from
CENUT will receive a booklet with detailed information
about a home exercise prescription, while the telehealth
programme will be maintained without supervision for
participants from TENUT. Instructions on performing
the home-based exercises and achieving dietary recommendations will be provided by the AEP and APD.
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